BOSTON, Sept. 15, 2026 (GLOBE NEWSWIRE) — Imbria Pharmaceuticals, Inc. (Imbria), a clinical-stage company developing innovative therapeutics for cardiovascular diseases, today announced that members of its executive leadership team will participate in several investor and industry conferences this fall, where they will discuss the Company’s corporate strategy, clinical development program, and the differentiated science behind ninerafaxstat, its investigational therapy for symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
“Imbria is entering an important phase of execution as we continue advancing ninerafaxstat through clinical development and delivering against key objectives,” said Alvin Shih, MD, Chief Executive Officer of Imbria Pharmaceuticals. “We look forward to engaging with the investment and broader life sciences community to share the progress of our FORTITUDE-HCM Phase 2b trial, highlight the science behind cardiac energetics, and discuss our vision for advancing a potential new treatment option for patients living with symptomatic nHCM.”
Members of Imbria’s leadership team will participate in panel discussions and fireside chats at the following conferences:
13th Annual World Medical Innovation Forum
Date: September 22–23, 2026
Location: Boston, MA
Format: Panel discussion
Panel: Heart of the Matter | Redefining Cardiovascular Care Beyond Statins
Session Date and Time: Wednesday, September 23, 11:00–11:40 a.m. ET
Speaker: Alvin Shih, MD, Chief Executive Officer
Stifel 2026 Virtual Cardiometabolic Forum
Date: September 30, 2026
Location: Virtual
Format: Fireside chat
Session Date and Time: Wednesday, September 30, 3:00–3:25 p.m. ET
Speaker: Alvin Shih, MD, Chief Executive Officer
Canaccord 2026 Biotech Private Company Symposium
Date: October 13, 2026
Location: Virtual
Format: Fireside chat
Session Date and Time: Tuesday, October 13, 10:00–10:25 a.m. ET
Speaker: Albert Kim, MD, PhD, Chief Medical Officer
About Imbria
Imbria Pharmaceuticals is a clinical-stage company developing innovative cardiovascular disease therapeutics by targeting cardiac energy metabolism. The company’s focus is ninerafaxstat, a differentiated, first-in-class cardiovascular therapy that acts by enhancing energy production in the heart. The FORTITUDE-HCM (NCT07023614) Phase 2b clinical trial is evaluating ninerafaxstat’s efficacy and safety in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), a debilitating disease with no currently approved treatments. For more information, visit http://www.FortitudeHCM.com/.
Based in the Boston area, Imbria is backed by a leading syndicate of investors, including RA Capital, SV Health Investors, Deep Track Capital, Catalio Capital Management, BNP Paribas, AN Ventures, and Cytokinetics. For more, visit www.Imbria.com.
Media Contact:
Sarah Hall
6 Degrees
(215) 313-5638
shall@6degreespr.com
